ArticlePloS one2026
Citrate supplement facilitated muscle growth and renal maturation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Citrate supplementation is well known to alleviate muscle fatigue. Furthermore, our previous clinical study revealed that citrate supplementation prevents renal oxidative stress and dysfunction. We hypothesize that an interaction between muscle and kidney tissues underlies the effects of citrate supplementation. This study investigated the effects of a citrate agent, potassium citrate/sodium citrate (PCSC), on muscle and renal functions. Male Sprague-Dawley rats were randomly assigned to two groups (control and PCSC groups). PCSC (2000 mg/kg body weight) was administered orally administrated for one week. Kidney weight, vastus lateralis muscle weight, and renal function were compared between the groups. Subsequently, the kidney and muscle tissues were analyzed using metabolomics. The PCSC group showed a significant increase in muscle mass relative to the weight gain (p = 0.0472). Renal function development with growth was more pronounced in the PCSC group (p < 0.0001). Metabolomic analysis of muscle tissue in the PCSC group revealed increased alanine levels and decreased levels of sarcosine, creatinine, and NADPH/NADP+ ratio. In the kidney tissue, PCSC supplementation led to elevated N,N-dimethylglycine, urea, and the ratio of malic acid to aspartate, while betaine aldehyde, carnitine, and Fisher's ratio decreased. The study concluded that PCSC supplement facilitated muscle growth metabolically through an alanine-associated pathway and renal function development by increasing intrarenal urea and accelerating the malate-shuttle and the betaine pathway. These findings indicate PCSC's potential impact of PCSCs on muscle-kidney interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.